On October 20,

2021 China Biotech Innovation Conference

was opened in CDHT,

in which China National Center for Biotechnology Development officially released

2021 Competitiveness Evaluation and Analysis Report of China Bioindustry Parks

and

“2020 Competitiveness Ranking of China Bioindustry Parks”.

In the competitiveness ranking of parks,

CDHT ranks the 4th place,

in the first matrix together with Suzhou Industrial Park,

Zhongguancun Science Park

and Shanghai Zhangjiang High-tech Industrial Development Zone.

 

CDHT ranks top 3 in terms of three primary indicators

including industrial competitiveness, talent competitiveness and environmental competitiveness.

 

 

       Since 2013, China National Center for Biotechnology Development has carried out competitiveness evaluation and analysis of China bioindustry parks for 7 times, continuously focusing on the development of biological medicine industry in China. In this Report, 121 national high-tech zones, 81 national economic development zones and 13 provincial and other parks (totally 215 parks) which completed the questionnaire survey were ranked in terms of competitiveness.

 

       B I O T I A N F U

       Improve the ability of achievement transformation and innovation

       Provide the whole-chain and whole-cycle industrial service system

       —

       The biomedical industry in CDHT is developing rapidly, ranking the first tier in the competitiveness of China bioindustry parks. Over 3,000 pharmaceutical enterprises are gathered in CDHT, including Sanofi, Gilead, Medtronic and AstraZeneca. CDHT attracts 7 teams winning the Nobel Prize and more than 100 national-level teams, where there are 10 listed and IPO-approved enterprises, and 48 first-type new drugs in the phase of clinical research.

 

 

       The first school-local cooperation model of "business partner" in China

 

       In 2018, Chengdu Advanced Medical Science Center co-built by the Management Committee of CDHT and Sichuan University took the lead in constructing the school-local cooperation model of "co-construction, co-management, sharing and co-service" in China, becoming an “accelerator” for the development of biological medicine industry in Chengdu.

 

Co-construction mode where the government constructs carriers and Sichuan University introduces projects

Co-management model of "work coordination and joint supervision of projects"

Sharing model where achievements are transferred into equity and equity can be swapped into options

Co-service model where knowledge is transformed to products, and professors serve as shareholders

 

 

       So far, Chengdu Advanced Medical Science Center has introduced 37 high-level R&D projects such as West China Biomedical Big Data Center, 12 transformation projects of professors from Sichuan University, and 16 major industry projects including West China headquarters of World Global 500 AstraZeneca. Besides, the Center attracts 2 academician talents, 8 national-level talents and nearly 2,000 technical talents.

 

       Chengdu Advanced Medical Science Center focuses on “innovation, R&D - achievement incubation - Industrialization implementation”, provides all-round one-stop services for projects and get through the "last mile" of R&D deliverable transformation. The team led by Academician Zhang Xingdong from Sichuan University provides technical guidance for us. At present, the team is carrying out the development of Class I, II and III medical instruments, such as customized 3D printed human tissue model and customized orthopedic surgical guide plates.

 

                                                                                                               - Fan Yujiang, Head of Beiya

 

 

       Construction of China's first pilot demonstration base for new drug development

 

       Four years ago, the Ministry of Science and Technology, the National Health and Family Planning Commission and the People's Government of Sichuan Province signed an agreement to facilitate the construction of "Pilot Demonstration Base for the Transfer and Transformation of Major National Science and Technology Achievements in the Innovation of New Drugs" by mainly relying on the Chengdu Tianfu International Biotown.

 

       Over the past four years, Phase I of the Pilot Demonstration Base has been completed, and 29 key techniques including targeted protein degradation technology have been broken through. Meanwhile, transfer and transformation of 879 new drug achievements have been undertaken. Therefore, a scientific research function platform based on real world research is built in CDHT, supporting the transformation of innovation achievements of a large number of biomedical enterprises in the zone.

 

 

       At present, a whole-chain technology innovation platform covering new drug R&D such as target discovery, drug screening, preclinical efficacy evaluation, safety evaluation, clinical trial, and pilot test enlargement has been built in CDHT.

 

       The construction of major platforms including the screening platform for lead DNA-encoded compound library, Hailan bioavailability evaluation platform, WestPoint large animal testing platform, and Conmed pilot scale production platform solve major problems concerning the transfer and transformation of new drug innovation achievements, break through the core and key bottleneck technologies from the development chain to the industrial chain, and create more 0-to-1 "hardcore techniques" and 1-to-N transformation achievements.

 

 

       Give a role of financial support

       Provide all-round support for enterprise listing

 

       On April 16, 2020, HitGen was successfully listed on the science and technology innovation board, which is the first enterprise in the West China listed on the science and technology innovation board. Later, bio-pharmaceutical enterprises in CDHT including Easton Biopharmaceuticals and OLYMVAX got listed on the science and technology innovation board. Conmed Biosciences was listed on the Hong Kong Stock Exchange. IPO of Hinova Pharma on the science and technology innovation board has been approved. The listing of Brilliant Pharmaceutical on the GEM has been approved. Clover Biopharmaceuticals has submitted the listing application to the Hong Kong Stock Exchange.

 

 

       In recent years, CDHT has constantly improved the cultivation service mechanism of listed backup enterprises, and built a one-stop comprehensive service platform for listed backup enterprises by focusing on the industrial ecosystem and technological innovation ecological chain, setting up a government service "green channel" for the listing of biomedical enterprises.

 

       The biomedicine investment and financing cooperation platform “circle of biomedicine funds” has been built. At present, more than 50 professional funds inside and outside Chengdu and nearly 100 investors have been gathered.

 

       CDHT has taken the lead in launching a series of credit products such as “BIO variety loan”, “BIO entry loan”, “BIO talent loan” and “BIO financing loan”, promoting national equity investment institutions to provide nearly RMB 5 billion of financing for pharmaceutical enterprises in the zone.

 

 

       Accelerate the construction of Chengdu Tianfu International Biotown

       Cultivate "fertile soil" for biomedical enterprises to grow

 

       Chengdu Tianfu International Biotown was co-built by CDHT and Shuangliu District, which is an important part of “one core and four districts” of Western (Chengdu) Science Town, and also Chengdu biomedical industry function zone. Over the five years, Chengdu Tianfu International Biotown is becoming “fertile soil” for biomedical enterprises to grow through industrial agglomeration and supporting facility improvement.

 

 

       A total of 150 projects have been settled in Chengdu Tianfu International Biotown, with the total investment amount of over RMB 110 billion. The overall planning of the industrial function zone has taken shape, and the industry chain continues to improve. Meanwhile, the innovation chain comes more perfect, the supply chain is becoming more professional, the factor chain continues to grow, and the value chain is deeply integrated.

 

       Following the construction logic of “people orientation, urban construction and industry foundation”, Chengdu Tianfu International Biotown takes the construction of "five-chain integration" bioindustry ecocircle and the construction of international livable quality park demonstration area as the implementation path. The 15-minute life service circle has basically taken shape.

 

Build an ecopark with the area of over 3 million square meters

Create a home of talents with the area of 400,000 square meters

The first international boat fishing base is settled in Chengdu

The talent apartments are sold out on the opening day

Wanhui Primary School and NOBO Kindergarten officially open

BOE, the largest digital hospital in South China, starts business

A large number of high-quality businesses have opened

 

 

CDHT

seizes the opportunity for the construction of the Chengdu-Chongqing economic circle,

and is accelerating to form an important growth pole

and a new driving force leading the high-quality development of the national bioindustry

by keeping the comprehensive competitiveness of the biomedicine park ranking first in China

 

 

 

Source: CDHT